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Introduction {#sec001}
============

Diffuse large B-cell lymphoma (DLBCL) is the most frequent type of lymphoma and is highly heterogeneous with regard to clinical manifestation, biological and molecular features and prognosis \[[@pone.0235786.ref001]--[@pone.0235786.ref003]\]. In eligible patients with refractory or recurrent DLBCL (r/rDLBCL) and transformed indolent lymphoma (r/rTRIL) the introduction of high-dose chemotherapy and autologous stem cell transplantation (SCT) following salvage immunochemotherapy led to long term survival rates of \>50% \[[@pone.0235786.ref004],[@pone.0235786.ref005]\]. Yet, up to 50% of initially transplant eligible patients are not able to receive autologous SCT due to failure of salvage therapy, failure of apheresis of autologous peripheral blood stem cells or therapy-limiting toxicity \[[@pone.0235786.ref005]\]. On the other hand, 40--50% of patients relapse within 4 years after autologous SCT \[[@pone.0235786.ref005]--[@pone.0235786.ref007]\], in that case resulting in very poor prognosis \[[@pone.0235786.ref008],[@pone.0235786.ref009]\]. In primary refractory DLBCL and DLBCL relapsing within 12 months after completion of first line therapy, lymphoma-directed myeloablative conditioning followed by allogeneic SCT may result in a better outcome compared to autologous SCT. Still, OS 1 year post allogeneic SCT does not exceed 50% \[[@pone.0235786.ref010]\]. Thus, the benefit of autologous and allogeneic SCT in r/rDLBCL and r/rTRIL is ultimately limited and therefore, pretherapeutic risk stratification to identify a subset of patients who will not benefit from SCT and should therefore be referred to alternative treatment approaches is an urgent need in clinical practice.

5--22% of transplant eligible r/rDLBCL patients show lymphoma infiltration of the bone marrow (BM) \[[@pone.0235786.ref005],[@pone.0235786.ref006],[@pone.0235786.ref011],[@pone.0235786.ref012]\]. In TRIL patients, up to 40% of BM involvement (BMI) has been reported \[[@pone.0235786.ref013]\]. While the BM is mostly concordantly involved by large cell lymphoma (conBMI), a subset of positive BMI (posBMI) patients show BMI by discordant small cell lymphoma (disBMI). The latter represents a heterogeneous group of disorders, comprising cases with clonally related, as well as cases with two clonally distinct, unrelated B-cell neoplasms presenting synchronously as previously shown by comparative molecular analysis of immunoglobulin heavy chain (IgH) and BCL2 gene rearrangements \[[@pone.0235786.ref014]\]. Since BMI is clinically recognized as advanced disease, it contributes to higher International Prognostic Index (IPI) scores \[[@pone.0235786.ref015]\]. However, it has been reported that conBMI but not disBMI negatively impacts progression free survival (PFS) and overall survival (OS) in DLBCL patients after treatment with front-line therapy independently from the IPI \[[@pone.0235786.ref016]--[@pone.0235786.ref018]\]. Yet, owing to the dissimilarity of designs and inclusion criteria and the limited number of enrolled patients with BMI in studies concerning r/rDLBCL and r/rTRIL, the prognostic impact of conBMI and disBMI in this patient group is unknown. In addition, clinicopathologic characteristics of posBMI primary and secondary r/rDLBCL patients are so far not well investigated. We retrospectively investigated a patient cohort intended to treat with autologous SCT to address these questions and elucidate the role of BMI in transplant eligible r/rDLBCL and r/rTRIL patients.

Patients and methods {#sec002}
====================

This is a retrospective single center analysis of unselected patients with transplant eligible r/rDLBCL and r/rTRIL patients who were treated between November 1998 and March 2019 at the University Hospital Halle (Saale). Patients were identified by a review of the internal hospital database records and verified by using the transplant-team records and German Registry for Stem Cell Transplantation (DRST) database. TRIL was defined as the presence of indolent B-cell lymphoma prior to or at the time of DLBCL diagnosis \[[@pone.0235786.ref006]\]. Only patients with histologically proven transformation were included. Patients were included in the analysis if they were ≥18 years of age with a biopsy proven diagnosis of DLBCL according to the 2008 WHO classification \[[@pone.0235786.ref019]\], were intended to treat with a consolidating SCT and had complete clinical data. Exclusion criteria comprised primary involvement of the central nervous system, primary mediastinal B-cell lymphoma or coincident medical conditions that precluded treating the lymphoma with curative intention. Assessed clinical data were age at relapse, sex, secondary age adjusted IPI (saaIPI) \[[@pone.0235786.ref020]\] (incorporating Ann Arbor staging \>II, elevated LDH and ECOG performance score \>1), TRIL, early relapse defined as duration of first complete remission \<12 months or incomplete response following front-line treatment, bulky mass ≥7,5 cm in largest diameter at any time before start of induction therapy \[[@pone.0235786.ref021]\], secondary involvement of the central nervous system (CNS), prior Rituximab application, executed SCT, remission status before SCT and histologically confirmed BMI any time prior to start of induction therapy.

BM biopsy were centrally reviewed at the Institute of Pathology, Halle (Saale) by the pathologists MB and CW. ConBMI was defined as BMI with DLBCL, while disBMI was reported if the histological und immunohistochemical picture was compatible with small cell B-cell lymphoma. Flow cytometry, immunohistochemistry and/ or next generation sequencing (NGS) based analysis of IgH gene rearrangements were utilized to confirm the clonality of the B-cell population or an aberrant immunophenotype when BM involvement was clinically highly suspicious and/or histology was inconclusive. All available lymphoma samples were immunohistochemically analyzed for GCB/ nonGCB status utilizing the classifier developed by Hans and colleagues \[[@pone.0235786.ref022]\]. In addition, available lymphoma tissue was immunohistochemically accessed for p53 alteration by IHC utilizing the p53 mouse monoclonal antibody (clone DO7, Cell Marque). A p53 overexpression and the lack of p53 immunohistochemical expression were considered positive \[[@pone.0235786.ref023]\]. Response to salvage therapy and, if applied, SCT was assessed by reviewing reports of contrasted computer tomography scans, magnetic resonance imaging (MRI) and/ or positron emission tomography with the tracer fluorine-18 fluorodeoxyglucose at time of relapse, after each line of salvage therapy and within three months after completion of SCT. Further, if BM was involved at any time before start of salvage therapy, remission assessment included the review of restaging BM biopsies. Response to salvage therapy was defined by achievement of at least partial remission (PR) defined by the diagnostic criteria of Lugano \[[@pone.0235786.ref024]\].

This study was performed according the Declaration of Helsinki and approved by the Ethics Committee at the Martin-Luther-University of Halle-Wittenberg (\#2019--072).

Statistical analyses {#sec003}
--------------------

Clinical characteristics were compared between the separate BMI cohorts using the independent samples t-test for continuous variables and the χ^2^ test for categorical variables. Progression free survival (PFS) was defined as the time from disease recurrence until lymphoma progression or death of any cause. In a landmark analysis for patients who received SCT, PFS post SCT was defined as the time from SCT until lymphoma progression or death of any cause. Overall survival (OS) was defined as the time from disease recurrence until death from any cause and OS post SCT was calculated from SCT until death from any cause. Patients were censored at time of their last clinical visit by a physician. OS and PFS were assessed using the Kaplan-Meier (KM) method \[[@pone.0235786.ref025]\]. The log-rank test \[[@pone.0235786.ref026]\] was utilized for comparison of PFS and OS between groups. Multivariate analysis was performed using a Cox proportional hazards model \[[@pone.0235786.ref027]\] to assess the independent effect of prognostic variables on PFS and OS. A P value of ≤0.05 (two-sided) was considered statistically significant. We used SPSS version 25.0 for Windows; SPSS Inc, Chicago, IL for data analysis.

Results {#sec004}
=======

Patient and treatment characteristics {#sec005}
-------------------------------------

A total of 82 patients with r/rDLBCL and r/rTRIL that met the inclusion criteria were identified. The median age of the entire cohort was 59 years (range, 23 to 75). At the time of analysis, median follow-up time for living patients was 66.3 months (range, 8.1 to 238.7). Overall, 58 patients (70.7%) have died. All patients have received front-line anthracycline-containing chemotherapy ([S1 Table](#pone.0235786.s002){ref-type="supplementary-material"}). Front-line therapy contained Rituximab in 59 patients (72%). Salvage immunochemotherapy comprised (R)-DHAP \[[@pone.0235786.ref005]\] in 40 patients (48.8%), (R)-ICE \[[@pone.0235786.ref005]\] in 14 patients (17.1%), (R)-DexaBEAM \[[@pone.0235786.ref028]\] in 15 patients (18.3%) and others in 13 patients (15.9%). Autologous SCT was accomplished in 57 patients (69.5%) ([Fig 1](#pone.0235786.g001){ref-type="fig"}). Out of these, 4 patients (4.9%) had tandem autologous and allogeneic SCT. Highdose chemotherapy regimens foregoing autologous SCT comprised BEAM \[[@pone.0235786.ref029]\] in 35 patients (61.4%), TEC \[[@pone.0235786.ref030]\] in 11 patients (19.3%) and other regimens in 11 patients (19.3%). Four patients (4.8%), in which autologous SCT was not executed due to insufficient disease control (n = 3, 3.6%) or failure of stem cell apheresis after induction immunochemotherapy (n = 1, 1.2%), were alternatively referred to allogeneic SCT. Patient and treatment characteristics are given in [Table 1](#pone.0235786.t001){ref-type="table"}.

![Consort diagram for the present DLBCL and TRIL patient cohort intended to treat with SCT.\
Abbreviations: r/r: recurrent or refractory, DLBCL: diffuse large B-cell lymphoma; SCT: stem cell transplantation, TRIL: transformed indolent lymphoma, CO: clinical option.](pone.0235786.g001){#pone.0235786.g001}
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###### Clinicopathologic characteristics of patients grouped by type of BMI.

![](pone.0235786.t001){#pone.0235786.t001g}

  *Chararacteristics*                                                                       *noBMI*       *conBMI*      *disBMI*                                         *P-value*                 
  ----------------------------------------------------------------------------------------- ------------- ------------- ------------------------------------------------ ----------- ------------- -----------
  *Age at relapse (years)*                                                                                                                                                                         
      *Median (Range)*                                                                      59 (23--75)   56 (36--71)   58 (51--65)                                      0.81        0.83          0.69
  *Sex*                                                                                                                                                                  0.381       **0.041**     0.199
      *Male*                                                                                42 (73.7)     12 (63.2)     2 (33.3)                                                                   
      *Female*                                                                              15 (26.3)     7 (36.8)      4 (66.7)                                                                   
  *saaIPI ≥2*                                                                               37 (64.9)     16 (84.2)     5 (83.3)                                         0.113       0.363         0.959
  *Bulky mass ≥7*.*5 cm*                                                                    21 (36.8)     4 (21.1)      2 (33.3)                                         0.205       0.865         0.539
  *Duration of first complete remission \<12 months*[\*](#t001fn002){ref-type="table-fn"}   41 (71.9)     11 (57.9)     2 (33)                                           0.254       0.053         0.294
  *TRIL*                                                                                    11 (19.3)     5 (26.3)      6 (100)                                          0.516       **\<0.001**   **0.002**
  *secondary CNS involvement*                                                               12 (17.5)     1 (5.3)       0 (0)                                            0.113       0.212         0.566
  *prior Rituximab treatment*                                                               44 (77.2)     11 (57.9)     4 (66.7)                                         0.103       0.565         0.702
  *failure to 1*^*st*^ *salvage regimen*                                                    22 (38.6)     5 (26.3)      3 (50)                                           0.333       0.587         0.278
  *completed SCT*                                                                           43 (75.4)     14 (73.7)     4 (66.7)                                         0.878       0.639         0.739
      *autologous SCT*                                                                      39 (68.4)     11 (57.9)     3 (50)                                                                     
      *allogeneic SCT*                                                                      2 (3.5)       0 (0)         2 (33.3)                                                                   
      *tandem SCT*                                                                          2 (3.5)       1 (15.3)      1 (16.7)                                                                   
  *no CR before SCT*                                                                        27 (62.8)     8 (57.1)      4 (100)[\*\*](#t001fn003){ref-type="table-fn"}   0.706       0.133         0.109
  *no CR after SCT*                                                                         17 (40.5)     6 (42.9)      2 (50)                                           0.875       0.712         0.8
  *COO (IHC)*                                                                                                                                                            **0.01**    0.06          0.43
      *GCB*                                                                                 17 (56.7)     3 (17.6)      0 (0)                                                                      
      *nonGCB*                                                                              13 (43.3)     14 (82.4)     3 (100)                                                                    
      *unknown*                                                                             27            2             3                                                                          
  *p53 expression (IHC)*                                                                                                                                                 0.088       0.184         0.859
      *p53 wt*                                                                              15 (71.4)     8 (44.4)      2 (40)                                                                     
      *p53 alteration*                                                                      6 (28.6)      10 (55.6)     3 (60)                                                                     
      *unknown*                                                                             36            1             1                                                                          

Abbreviations: BMI: bone marrow infiltration, noBMI: no bone marrow infiltration, conBMI: concordant bone marrow infiltration, disBMI: discordant bone marrow infiltration, saaIPI: secondary age adjusted International Prognostic Index, TRIL: transformed indolent lymphoma, CNS: central nervous system, SCT: stem cell transplantation, CR: complete remission, COO: cell of origin, IHC: immunohistochemistry, GCB: germinal center B-cell, wt: wildtype

\*including patients not achieving complete response after front-line treatment

\*\*2 (50%) no response of indolent component, 2 (50%) no response of aggressive component.

### Characteristics of patients with BMI {#sec006}

A total of 25 patients (31.5%) had BMI at any time before start of induction therapy. Of these, 19 patients (23.2%) had conBMI and 6 patients (7.3%) had disBMI. Two patients with inconclusive BM histology were clinically suspicious for conBMI and showed a clonal B-cell population in BM accessed by NGS and were therefore assigned to the conBMI patient group. 57 patients (68.5%) had noBMI (noBMI). [Table 1](#pone.0235786.t001){ref-type="table"} summarizes the clinicopathological and therapy associated characteristics for each of the three groups. Comparing all three groups, the noBMI, conBMI and disBMI group, we found no relevant difference in age, saaIPI, bulky disease, secondary CNS involvement, duration of first complete remission, prior Rituximab treatment, front-line regimens and completion of SCT. TRIL was more often diagnosed in patients with disBMI (disBMI 100% vs. conBMI 26.3% and noBMI 19.3%, p \<0.01, respectively). The conBMI group was more likely to express a nonGCB immunophenotype as classified by the HANS algorithm compared to the noBMI group (82.4% vs. 43.3%, p = 0.01). Alteration of p53 was equally distributed between the BMI groups. The same observations were made when conBMI and disBMI were compared to the patient group with extensive disease (AA \>2) and noBMI, respectively ([S2 Table](#pone.0235786.s003){ref-type="supplementary-material"}). An enrichment of secondary CNS involvement was only observed when comparing patients with AA \>2 and noBMI to the conBMI group (AA\>2, noBMI 27.3% vs. conBMI 5.3%, p = 0.048).

Response to salvage therapy according to BMI {#sec007}
--------------------------------------------

As expected, failure of salvage therapy in the entire cohort was significantly associated with early relapse (37% vs 7%, p = 0.004), bulky disease (52% vs 15%, p = 0.001) and female sex (46% vs 18%, p = 0.007). No relevant differences in response were found according to salvage chemotherapy regimens and if applied high-dose chemotherapy regimens foregoing autologous SCT. Also, patients who responded to salvage chemotherapy were more likely to proceed to SCT (92% vs 8%, p \<0.001) ([S3 Table](#pone.0235786.s004){ref-type="supplementary-material"}).

Interestingly, no correlation of posBMI with response to salvage therapy was observed, as noBMI and posBMI patients showed a similar response rate (28% vs 26%, p = 0.874).

Impact of BMI on survival {#sec008}
-------------------------

[Table 2](#pone.0235786.t002){ref-type="table"} and [S4 Table](#pone.0235786.s005){ref-type="supplementary-material"} summarize the results of all tested variables in uni- and multivariate survival analyses. BMI negatively affected survival (posBMI vs noBMI: median PFS 9.2 vs. 17.45 months, log-rank (KM) p = 0.055; median OS, 13.54 vs 28.91 months, log-rank (KM) p = 0.022; [S1A Fig and S1B Fig](#pone.0235786.s001){ref-type="supplementary-material"}). Importantly, conBMI portended a poor prognosis relative to noBMI (median PFS, 9.2 vs 17.45 months, log rank (KM) p = 0.049; median OS, 14.72 vs 28.91 months, log-rank (KM) p = 0.017, [Fig 2A and 2B](#pone.0235786.g002){ref-type="fig"}), whereas disBMI did not (median PFS, 6 vs 17.45 months, log rank (KM) p = 0.456; median OS, 11.89 vs 28.91; log rank (KM) p = 0.4; [S1C Fig and S1D Fig](#pone.0235786.s001){ref-type="supplementary-material"}). ConBMI maintained its prognostic relevance towards noBMI in the landmark PFS and OS analyses of the transplanted cohort ([Fig 2C and 2D](#pone.0235786.g002){ref-type="fig"}), in the extensive disease cohort ([S1E Fig and S1F Fig](#pone.0235786.s001){ref-type="supplementary-material"}) and in the nonGCB cohort ([S1G Fig and S1H Fig](#pone.0235786.s001){ref-type="supplementary-material"}).

![Kaplan-Meier curves for progression free survival and overall survival according to different groups of BMI.\
a: KM curve for PFS according to noBMI vs conBMI in the total cohort; b: KM curve for OS according to noBMI vs conBMI in the total cohort; c: KM curve for PFS landmark analysis according to noBMI vs conBMI in the transplanted patient subset; d: KM curve of OS landmark analysis according to noBMI vs conBMI in the transplanted patient subset; Abbreviations: BMI: bone marrow infiltration, noBMI: no bone marrow infiltration, conBMI: concordant bone marrow infiltration, KM: Kaplan-Meier; PFS: progression free survival, OS: overall survival, N: number of patients, cens.: censored.](pone.0235786.g002){#pone.0235786.g002}
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###### Prognostic factors of OS in r/rDLBCL and r/rTRIL patients, transplant eligible.

![](pone.0235786.t002){#pone.0235786.t002g}

                                                           total cohort (n = 82)   landmark analysis of the transplanted cohort (n = 61)                                                                              
  -------------------------------------------------------- ----------------------- ------------------------------------------------------- ------- ------------ ----------- ------- ------------- ------ ------------ -----------
  *Age at relapse*                                                                                                                         1.01    0.99--1.04   0.319                             1.01   0.98--1.03   0.635
  *Sex*                                                                            0.057                                                   1.64    0.91--2.96   0.103               0.661         1.19   0.56--2.53   0.643
      *Male*                                               28.91                                                                                                            37.98                                     
      *Female*                                             11.89                                                                                                            23.79                                     
  *saaIPI*                                                                         **0.01**                                                1.57    0.79--3.2    0.203               0.1           1.53   0.7--3.32    0.286
      *saaIPI \<2*                                         96.16                                                                                                            90.22                                     
      *saaIPI ≥2*                                          12.78                                                                                                            14.1                                      
  *TRIL*                                                                                                                                   1.4     0.69--2.81   0.35                0.185         1.72   0.73--4.04   0.213
      *dnDLBCL*                                            30.23                   0.089                                                                                    37.98                                     
      *TRIL*                                               12.78                                                                                                            14                                        
  *Bulky mass ≥7*.*5 cm*                                                           **0.001**                                               1.91    0.95--3.83   0.068               0.072         1.53   0.61--3.83   0.362
      *no*                                                 36.7                                                                                                             37.98                                     
      *yes*                                                8.44                                                                                                             5.29                                      
  *Duration of first CR*                                                           **0.021**                                               2.27    1.07--4.81   **0.032**           0.284         1.28   0.58--2.83   0.532
      *\<12 months*[\*](#t001fn003){ref-type="table-fn"}   11.9                                                                                                             14                                        
      *≥12 months*                                         43.96                                                                                                            38.87                                     
  *BMI*                                                                            **0.022**                                                                                        **0.041**                         
      *noBMI*                                              28.91                                                                                                            66.86                                     
      *posBMI*                                             13.54                                                                                                            14                                        
          *conBMI*                                         14.72                   **0.017**                                               2.76    1.43--5.31   **0.002**   14      **0.025**     2.63   1.19--5.79   **0.017**
          *disBMI*                                         11.89                   0.4                                                     1.47    0.42--5.14   0.543       7.1     0.587         0.62   0.12--3.23   0.572
  *prior Rituximab treatment*                                                      0.315                                                                                            0.627                             
      *no*                                                 43.96                                                                                                            37.98                                     
      *yes*                                                13.54                                                                                                            28.39                                     
  *response to first salvage*                                                      **0.006**                                                                                        **\<0.001**                       
      *no*                                                 9.3                                                                                                              4.34                                      
      *yes*                                                36.7                                                                                                             38.87                                     
  *undergone SCT*                                                                  **\<0.001**                                             0.313   0.16--0.63   **0.001**                                             
      *no*                                                 7                                                                                                                                                          
      *yes*                                                36.7                                                                                                                                                       
  *remission status before SCT*                                                                                                                                                     **0.008**     2.64   1.19--5.87   **0.017**
      CR                                                                                                                                                                    82.46                                     
      ≥PR                                                                                                                                                                   7.8                                       
  *COO (IHC)*                                                                      0.379                                                                                            0.78                              
      *GCB subtype*                                        26.89                                                                                                            28.39                                     
      *nonGCB subtype*                                     18.86                                                                                                            25.79                                     
  *p53 expression (IHC)*                                                           0.451                                                                                            0.191                             
      *p53 wt*                                             19.09                                                                                                            28.39                                     
      *p53 alteration*                                     13.54                                                                                                            23.79                                     

Abbreviations: OS: overall survival, r/r: recurrent or refractory, DLBCL: diffuse large B-cell lymphoma, TRIL: transformed indolent lymphoma, HR: Hazard Ratio, CI: Confidence Interval, saaIPI: secondary age adjusted International Prognostic Index, dnDLBCL: de novo diffuse large B-cell lymphoma, SCT: stem cell transplantation, BMI: bone marrow infiltration, noBMI: no bone marrow infiltration, posBMI: positive bone marrow infiltration, conBMI: concordant bone marrow infiltration, disBMI: discordant bone marrow infiltration, SCT: stem cell transplantation, CR: complete remission, PR: partial remission, COO: cell of origin, IHC: immunohistochemistry, GCB: germinal center B-cell, wt: wildtype

\*including patients not achieving complete response after front-line treatment.

In multivariate analysis utilizing Cox regression model of PFS and OS, conBMI and not performed SCT were adverse prognostic factors for both PFS and OS (PFS: [S4 Table](#pone.0235786.s005){ref-type="supplementary-material"}, OS: [Table 2](#pone.0235786.t002){ref-type="table"}). Additionally, early relapse predicted poor OS in multivariate analysis. Sex, TRIL, saaIPI ≥2, bulky mass ≥7.5 cm and disBMI showed no prognostic relevant impact ([Table 2](#pone.0235786.t002){ref-type="table"}). We also, separately, performed exploratory multivariate landmark analyses within the subgroup of transplanted patients, to determine if the risk factors for mortality or relapse were different in this group. In transplanted patients, non-achievement of complete remission (CR) before SCT was included into the multivariate analysis and was strongly associated with worse postSCT PFS and OS ([S4 Table](#pone.0235786.s005){ref-type="supplementary-material"}, [Table 2](#pone.0235786.t002){ref-type="table"}). Of note, conBMI also maintained its prognostic relevance in multivariate landmark analysis in the transplanted patient subset ([S4 Table](#pone.0235786.s005){ref-type="supplementary-material"}, [Table 2](#pone.0235786.t002){ref-type="table"}).

Discussion {#sec009}
==========

To the best of our knowledge, we present the first detailed analysis of the prognostic impact of BMI on outcome of transplant eligible r/rDLBCL and r/rTRIL patients. In this analysis, conBMI but not disBMI was associated with worse PFS and OS in transplant eligible patients. This association was irrespective of Ann Arbor stage and saaIPI indicating conBMI might not only be a measure of the extend of the disease.

As reported previously \[[@pone.0235786.ref004]--[@pone.0235786.ref006],[@pone.0235786.ref031],[@pone.0235786.ref032]\], early relapse, achievement of CR preceding SCT and completion of SCT, which was strongly associated with response to the salvage therapy (91.2% vs 4%, p \<0.001), displayed strong factors for PFS and OS in our analyses. Taken together, these parameters emphasize the main limitation of the SCT strategy since response to chemotherapy remains a fundamental prerequisite for SCT. Further parameters, which were able to discriminate subgroups of patients with differing prognosis in our study include saaIPI ≥2 \[[@pone.0235786.ref020],[@pone.0235786.ref033]\] and bulky disease \[[@pone.0235786.ref021],[@pone.0235786.ref034]\]. However, while these parameters impacted survival in univariate analyses, they failed to show relevant influence on PFS and OS in multivariate analyses of the transplanted subgroup if achievement of CR before SCT was included into the model. This suggests that these factors indicate the likelihood of achieving CR after salvage immunochemotherapy ([S3 Table](#pone.0235786.s004){ref-type="supplementary-material"}), rather than affecting the outcome of SCT for patients who do reach CR \[[@pone.0235786.ref006]\]. In contrast to these findings, conBMI but not disBMI portended worse PFS and OS compared to the noBMI group independently from other prognostically relevant factors.

In analogy to findings in first diagnosed DLBCL \[[@pone.0235786.ref035]\], alteration of p53 expression, which is a known marker for high clinical stage \[[@pone.0235786.ref036]\] but not for adverse survival \[[@pone.0235786.ref037]\], was not associated with BMI subgroups in the present cohort. On the other hand, conBMI was significantly associated with nonGCB subtype as classified by the Hans-algorithm \[[@pone.0235786.ref022]\], which is in opposition to findings in front-line setting of DLBCL \[[@pone.0235786.ref035]\]. Yet, the prognostic impact of conBMI appears to be independent from the cell of origin subtype as it maintained its prognostic relevance both, in the GCB and the in the nonGCB cohort. Recently, Yao et al. \[[@pone.0235786.ref035]\] reported on broader biological characteristics in initially diagnosed DLBCL patients, revealing that conBMI also shows an enrichment for unfavorable markers such as CD5 expression \[[@pone.0235786.ref038]\] and MYC gene rearrangement \[[@pone.0235786.ref039]\]. Yet, of interest, conBMI remained an adverse predictor in almost all tested biomarker-positive DLBCL subsets. The authors thus assumed that conBMI may not be entirely a surrogate for these known adverse biological features in DLBCL, but other possible mechanisms underlying conBMI may contribute to adverse survival. In their study, gene expression profiling of DLBCL specimen in the reported cohort revealed that conBMI in comparison to noBMI additionally shows an upregulation of genes encoding various proteins playing a key role in cellular adhesion or cytoskeletal reorganization as well as immunoregulation \[[@pone.0235786.ref035]\]. Therefore, conBMI may be related to cellular adhesion or migration and immune tolerance or escape within the BM niche. Further, adhesion of DLBCL to stroma cells within the BM niche could explain drug resistance and therefore limited prognosis \[[@pone.0235786.ref040]\].

The results from our studied patient cohort, which is comparable in terms of basic patient and disease characteristics to transplant eligible r/rDLBCL patients treated within prior prospective trials \[[@pone.0235786.ref005],[@pone.0235786.ref031],[@pone.0235786.ref041]\] underline the hypothesis that conBMI expresses an easy to access surrogate for an underlying unfavorable lymphoma biology in the second-line setting of DLBCL and TRIL. However, the current results are subject to several limitations mainly caused by the retrospective character of this analysis and the heterogeneity of the described cohort. Further, the relatively small patient size increases the risk of statistical errors.

Nonetheless, based on the presented data, we consider conBMI to be a relevant and independent clinical marker for poor prognosis in r/rDLBCL and r/rTRIL patients. Since incorporating conBMI in the pretherapeutic assessment could improve our ability to risk stratify patients with r/rDLBCL considering SCT, we hope that the results presented here may be further validated and enable precise prognostication and individualized disease surveillance as well as contribute to the design of upcoming clinical trials. Moreover, as the mechanisms underlying conBMI are not fully elucidated, further investigation of the biological background of DLBCL with conBMI is needed to identify potential therapeutic targets.

Supporting information {#sec010}
======================

###### Kaplan-Meier curves for progression free survival and overall survival according to different groups of BMI.

a: KM curve for PFS according to noBMI vs BMI in the total cohort; b: KM curve for OS according to noBMI vs BMI in the total cohort; c: KM curve for PFS according to noBMI vs disBMI in the total cohort; d: KM curve of OS acc ording to noBMI vs disBMI in the total cohort; e: KM curve for PFS according to noBMI vs conBMI in the extensive disease (AA\>2) patient subset, f: KM curve for OS according to noBMI vs conBMI in the extensive disease (AA\>2) patient subset; g: KM curve for PFS according to noBMI vs conBMI in the nonGCB patient subset; h: KM curve for OS according to noBMI vs conBMI in nonGCB patient subset; Abbreviations: BMI: bone marrow infiltration, noBMI: no bone marrow infiltration, conBMI: concordant bone marrow infiltration, KM: Kaplan-Meier; PFS: progression free survival, OS: overall survival, AA: Ann Arbor, GCB: germinal center B-cell.

(TIFF)

###### 

Click here for additional data file.

###### Front-line regimens of patients grouped by type of BMI.

Abbreviations: BMI: bone marrow infiltration, noBMI: no bone marrow infiltration, conBMI: concordant bone marrow infiltration, disBMI: discordant bone marrow infiltration, CHOP: cyclophosphamide, hydroxydaunorubicin, vincristine, prednisolone, R: rituximab, CHOEP: cyclophosphamide, hydroxydaunorubicin, vincristine, etoposide, prednisolone, DA-EPOCH-R: dose adjusted etoposide, prednisolone, vincristine, cyclophosphamide, doxorubicin, rituximab.

(XLSX)
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Click here for additional data file.

###### Clinicopathologic characteristics of patients with extensive disease defined as AA \>2 grouped by type of BMI.

Abbreviations: AA: Ann Arbor stage, BMI: bone marrow infiltration, noBMI: no bone marrow infiltration, conBMI: concordant bone marrow infiltration, disBMI: discordant bone marrow infiltration, saaIPI: secondary age adjusted International Prognostic Index, TRIL: transformed indolent lymphoma, CNS: central nervous system, SCT: stem cell transplantation, CR: complete remission, COO: cell of origin, IHC: immunohistochemistry GCB: germinal center B-cell, wt: wildtype; \*including patients not achieving complete response after front-line treatment.

(XLSX)
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Click here for additional data file.

###### Best response to salvage therapy without SCT according to prognostic factors.

Abbreviations: SCT: stem cell transplantation, CR: complete remission, PR: partial remission, SD: stable disease, PD: progressive disease, BMI: bone marrow infiltration, noBMI: no bone marrow infiltration, posBMI: positive bone marrow infiltration, saaIPI: secondary age adjusted International Prognostic Index, TRIL: transformed indolent lymphoma, dnDLBCL: de novo diffuse large B-cell lymphoma, SCT: stem cell transplantation, CTx: chemotherapy, COO: cell of origin, IHC: immunohistochemistry, GCB: germinal center B-cell, wt: wildtype; \*response to autologous SCT.

(XLSX)
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Click here for additional data file.

###### Prognostic factors of PFS in r/rDLBCL and r/rTRIL patients, transplant eligible.

Abbreviations: PFS: progression free survival, r/r: recurrent or refractory, DLBCL: diffuse large B-cell lymphoma, TRIL: transformed indolent lymphoma, HR: Hazard Ratio, CI: Confidence Interval, saaIPI: secondary age adjusted International Prognostic Index, dnDLBCL: de novo diffuse large B-cell lymphoma, SCT: stem cell transplantation, BMI: bone marrow infiltration, noBMI: no bone marrow infiltration, posBMI: positive bone marrow infiltration, conBMI: concordant bone marrow infiltration, disBMI: discordant bone marrow infiltration, SCT: stem cell transplantation, CR: complete remission, CR: complete remission, PR: partial remission, COO: cell of origin, IHC: immunohistochemistry, GCB: germinal center B-cell; \*including patients not achieving complete response after front-line treatment.

(XLSX)
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Click here for additional data file.
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Dear Dr. Weber,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process by both reviewers, experts in the lymphoma field.

We would appreciate receiving your revised manuscript by May 23 2020 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Francesco Bertolini, MD, PhD

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1\. Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at

<http://www.journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf> and <http://www.journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf>

2\. Please provide a sample size and power calculation in the Methods, or discuss the reasons for not performing one before study initiation.

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: This paper contributes to the field of prognostic factors in relapsed or refractory (R/R) diffuse large B cell (DLBCL) or transformed indolent (TRIL) non Hodgkin lymphoma. This is a retrospective observational single center study on the prognostic role of bone marrow involvement (BMI) by large B cell (concordant involvement) or by small cell (discordant involvement) lymphoma in 82 patients with transplant eligible recurrent or refractory DLBCL or TRIL treated with salvage chemotherapy over 20 years (from 1998 to 2019). The study clarifies that concordant but not discordant bone marrow involvement was responsible for a lower progression-free and overall survival in the whole patient population and in the subset of those patients who were able to receive a transplant. The authors recognize the limits of their study, mainly related to the retrospective analysis and to the small patient population of each subgroup (no BMI, n=57, vs concordant BMI, n=19, vs discordant BMI, n=6). Nevertheless, the observation that patients presenting with concordant BMI had 2.34 risk to fail salvage treatment, with or without autologous stem cell or allogeneic transplant, and 2.77 risk to die compared to their counterpart without BMI or with discordant BMI may help change clinical practice in this poor prognosis subgroup of R/R DLBCL or TRIL and therefore the study is worthwhile to be published.

Major Comments:

Abstract, page 2: Authors should include a definition of concordant and discordant BMI also in the abstract section

Patients and Methods pag 4: Authors should report how patients were selected: from a database, from a review of medical records, a review of all the histological diagnosis of NHL; how many patients with DLBCL were treated with frontline and/or salvage therapy in the same period?

Results, Patient and treatment characteristics, pag 6: Authors should report in details the front-line regimens used in a supplemental table

Results, response to salvage therapy, page 10: In S2 table patients with refractory disease and those with relapse within 12 months should be listed and analyzed separately.

Was there any difference in response rate based on salvage induction chemotherapy or myeloablative regimen?

Figure 2 a-d: Authors should report number of patients at risk

Reviewer \#2: - In Table 1 remission duration \< 12 month specify first remission

\- Specify if in Table 1 no CR before SCT for dis BMI was due to non response of aggressive component, indolent component or both

\- Some more information could be interesting:

1\. any data about p53 disruption in all three groups? Expecially for disBMI

2\. it could be important to have data about IGH rearragment in trasformed lymphoma, same rearragment and two different clone may have different outcome.

3\. any data about FISH analysis for MYC, BCL2 and BCL6.

4\. any data about risk of CNS involvement between no BMI an BMI?

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: Yes: Simonetta Viviani

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.

10.1371/journal.pone.0235786.r002

Author response to Decision Letter 0

2 Jun 2020

In general:

We identified two minor mistakes in our statistics. We corrected all affected parameters in the revised manuscript. No relevant changes in significance levels occurred.

We corrected some spelling errors.

Reviewer 1:

1\. Abstract, page 2: Authors should include a definition of concordant and discordant BMI also in the abstract section:

We included the definition in the abstract on page 2 lines 6-9.

2\. Patients and Methods page 4: Authors should report how patients were selected: from a database, from a review of medical records, a review of all the histological diagnosis of NHL:

Patients were identified from a review of medical records in the internal hospital database. Patients were verified by using the transplant-team records and German Registry for Stem Cell Transplantation (DRST) database. We identified 82 patients and included all in the analyses.

We added a statement in the methods section on page 4 lines 19-21.

3\. How many patients with DLBCL were treated with frontline and/or salvage therapy in the same period?

We thank the reviewer for this important question. To the best of our knowledge, we included all transplant eligible patients of this time interval in our analysis.

We double-checked the number of patients by tracking the ICD10 codes for DLBCL retrospectively in our electronic inhouse database from 2015 to 2019 (when ICD-10 tracking was available). Using this method, we identified 126 patients with DLBCL or TRIL from 2014 to 2019 who received treatment at our institution. Out of these 73 patients (59%) received solely front-line treatment and 52 patients with rrDLBCL and rrTRIL (41%) received salvage immunochemotherapy. 32 of 52 patients with rrDLBCL or rrTRIL (62%) were considered initially transplant eligible. All 32 were included in our analysis. Thus, we assume that a representative proportion of patients with rrDLBCL and rrTRIL was included overall in our study.

4\. Results, Patient and treatment characteristics, pag 6: Authors should report in details the front-line regimens used in a supplemental table.

We added the front-line regimens in the new table S1.

5\. Results, response to salvage therapy, page 10: In S2 table patients with refractory disease and those with relapse within 12 months should be listed and analyzed separately.

We thank the reviewer for pointing to this important aspect. We added this information now in table S3.

6\. Was there any difference in response rate based on salvage induction chemotherapy or myeloablative regimen?

No relevant differences in response were found according to salvage chemotherapy regimens and if applied high-dose chemotherapy regimens foregoing autologous SCT. We added information on response rates based on salvage induction and myeloablative regimen foregoing autologous SCT in table S3 and within the manuscript in Results, page 11 line 25 to page12 line 3.

7\. Figure 2 a-d: Authors should report number of patients at risk.

We added the number of patients at risk in figure 2a-d.

Reviewer 2:

1\. In Table 1 remission duration \< 12 months specify first remission.

We thank the reviewer for pointing out this important aspect. In the current work, we defined remission according to the CORAL stud by Gisselbrecht et al. (J Clin Oncol. 2010;28:4184--90): a) in complete remission after front line treatment, relapsed after 12 months, b) in complete remission after front line treatment, relapsed within 12 months, c) no achievement of complete remission after front line treatment (incomplete response). In our analysis we compared patient group a) vs. b) and c) ("early relapse"), since they show similar impact on survival after completed autologous SCT as shown within the PARMA trial (Philip et al.; N Engl J Med. 1995;333:1540--5.) We now specified the remission duration in table 1 (duration of first complete remission \<12 months) and its legend ("\*including patients not achieving complete response after front-line treatment". We also specified this aspect in the Methods section page 5, line 6-8 ("early relapse defined as duration of first complete remission \<12 months after completed front-line treatment including incomplete remission).

2\. Specify if in Table 1 no CR before SCT for dis BMI was due to non-response of aggressive component, indolent component or both:

We specified the reason of not achieving complete remission in the legend of table 1: "2 (50%) no response of indolent component, 2 (50%) no response of aggressive component".

3\. Some more information could be interesting:

3.1. Any data about p53 disruption in all three groups? Expecially for disBMI.

As Sanger sequencing was unavailable due to institutional COVID19-regulations, we performed p53-expression analyses by routine automatized immunohistochemical assessment using the Cell Marque anti-p53-antibody clone DO7. A reduced expression or overexpression was defined as altered TP53-status. We added this in Methods on page 5, line 22-25. In our present cohort, alteration of p53 expression was not associated with BMI subgroups and did not affect survival. We added this information within table 1-2, S2-4 table and the discussion section page 17, line 23 to page 18 line 1.

3.2. It could be important to have data about IGH rearrangement in transformed lymphoma, same rearrangement and two different clone may have different outcome.

We thank the reviewer for bringing up this very interesting aspect. Unfortunately, we were not able to perform NGS on TRIL tissue during the given time due to institutional COVID-19 regulation. We hope to perform this analysis in nearby future.

3.3. Any data about FISH analysis for MYC, BCL2 and BCL6.

This is an important point. We performed MYC, BCL2 and BCL6 breakpoint analyses by CISH. Unfortunately, we did not obtain utilizable results. Inter alia, this is due to the FFPE-material with unbuffered paraffin used in our institution until 2010.

3.4. Any data about risk of CNS involvement between no BMI and BMI?

We thank the reviewer for making this point. An enrichment of secondary CNS involvement was only observed when comparing patients with extensive disease and noBMI vs. conBMI (AA\>2, noBMI (n=12, 27.3%) vs. conBMI (n=1, 5.3%, p =0.048). This is in opposition to the association of BMI and risk of CNS relapse in the first line setting. However, in opinion numbers are too small to draw further conclusions. We included secondary CNS involvement in Methods, page 5, lines 9-10. The distribution of CNS involvement between patient groups was included in table 1 and in Results page 11 lines 18-20.

###### 

Submitted filename: Response to Reviewers_07437R1.docx

###### 

Click here for additional data file.

10.1371/journal.pone.0235786.r003

Decision Letter 1

Bertolini

Francesco

Academic Editor

© 2020 Francesco Bertolini

2020

Francesco Bertolini

This is an open access article distributed under the terms of the

Creative Commons Attribution License

, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

23 Jun 2020

Impact of Bone Marrow Involvement on Outcome in relapsed and refractory transplant eligible Diffuse Large B-Cell Lymphoma and Transformed Indolent Lymphoma

PONE-D-20-07437R1

Dear Dr. Weber,

We're pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you'll receive an e-mail detailing the required amendments. When these have been addressed, you'll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at <http://www.editorialmanager.com/pone/>, click the \'Update My Information\' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they'll be preparing press materials, please inform our press team as soon as possible \-- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

Kind regards,

Francesco Bertolini, MD, PhD

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: All comments have been addressed

Reviewer \#2: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: (No Response)

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: (No Response)

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: (No Response)

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: (No Response)

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: (No Response)

Reviewer \#2: Thank you for updating the paper. I found the additional informations quites interesting. I\'ve no other questions
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7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: Yes: Simonetta Viviani

Reviewer \#2: No
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Dear Dr. Weber:

I\'m pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they\'ll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

If we can help with anything else, please email us at <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE and supporting open access.
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PLOS ONE Editorial Office Staff
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